RPG Life Sciences (RPGLIFE) Q4 24/25 earnings summary

Executive summary

• FY25 revenue grew 12% to ₹653.4 Cr, with strong profit growth and margin expansion across all business segments.

• Net profit for the year was ₹18,324 lakhs, more than double the previous year's ₹8,766 lakhs, aided by exceptional profit from land assignment and offset by a fire incident.

• Six-year trajectory shows sales up 2.2x, EBITDA up 5x, PBT up 10x, PAT up 11x, and significant margin expansion.

• Transformation agenda focused on execution, digitalization, and sustainable operations drove operational excellence.

• Recognized among India's Top 500 Value Creators and for fair business practices, with multiple industry awards.

Financial highlights

• Q4 FY25 revenue was ₹143.1 Cr, up 13% year-over-year; Q4 EBITDA up 37%, PAT up 40%, and EBITDA margin rose from 17.6% to 21.4%.

• Full year EBITDA margin increased from 23% to 26.4%, PAT margin from 15% to 17.1%, and EPS grew to ₹67.5.

• Profit before tax (including exceptional items) for FY25 was ₹23,288 lakhs, up from ₹11,784 lakhs.

• Cash surplus reached INR 266 crore, including operational surplus and exceptional items.

• Excluding exceptional items, margins and profits showed consistent upward trends.

Outlook and guidance

• All business segments (domestic, international, API) expected to drive growth, supported by modernized plants, new product pipeline, and capacity expansion.

• API business to see growth from 12 new molecules by end FY26/FY27; international formulations to benefit from new launches and market expansion.

• R&D spend expected to remain at 2-3% of sales, possibly rising as more molecules are developed.

• Board recommended a final dividend of ₹20 per share and a special dividend of ₹4 per share, subject to shareholder approval.

• M&A opportunities and adjacent market exploration are part of the growth strategy.